Stock comparison
Halozyme Therapeutics
Iovance Biotherapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
IOVA
Iovance Biotherapeutics
Market cap
$1.47B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | IOVA | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 24F | HALO |
| Benjamin Graham | 83A | 41D | HALO |
| Philip Fisher | 65B | 39D | HALO |
| Peter Lynch | 53D | 3F | HALO |
| Joel Greenblatt | 40D | 2F | HALO |
| Charlie Munger | 80C | 28F | HALO |
| Terry Smith | 84A | 33F | HALO |
Side-by-side metrics
| Metric | HALO | IOVA |
|---|---|---|
| Market cap | $8.1B | $1.47B |
| P/E (TTM) | 24.0x | - |
| EV/EBIT | 10.2x | - |
| ROIC (TTM) | 23.65% | -45.33% |
| Gross margin | 81.24% | 114.51% |
| Net margin | 23.13% | -123.9% |
| Revenue CAGR 5y | 33.23% | - |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- ROIC (TTM)23.65%vs -45.33%+152%
- Net margin23.13%vs -123.9%+119%
- Market cap$8.1Bvs $1.47B+82%
IOVA leads on
- EV/EBIT-vs 10.2x+125%
- P/E (TTM)-vs 24.0x+116%
- Debt / Equity0.1xvs 1.0x+93%
- Gross margin114.51%vs 81.24%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.